New combo therapy aims to stall lung cancer progression
NCT ID NCT04743505
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the experimental drug APL-101 to standard osimertinib can better control EGFR-mutated metastatic non-small cell lung cancer. About 27 adults who have already started osimertinib without their cancer getting worse will receive the combination until the disease progresses. The goal is to find the safest dose and see if it delays cancer growth.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Can a pill outperform chemo for a Hard-to-Treat lung cancer mutation?
- Can a new drug shrink Hard-to-Treat tumors?
- Breath test may reveal who benefits from lung cancer immunotherapy
- Targeted radiation and immunotherapy join forces against Hard-to-Treat lung cancer
- Triple-Drug cocktail targets tough lung cancer mutations